OGN Stock Recent News

SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Organon & Co. (NYSE: OGN). Investors who purchased shares of Organon & Co. (NYSE: OGN) prior to October 2024 and continue to hold any of those NYSE: OGN shares, also have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines; cost-cutting helps margins, but can't reverse the downward trend in earnings. Valuation discounts already reflect worst-case scenarios; fair value is around $9 per share, leaving little upside unless growth drivers emerge.

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new products like Emgality and VTAMA are not offsetting losses from older drugs. Women's Health and Biosimilars show some growth, but not enough to reverse the overall negative trend or justify optimism.

Organon (OGN) Fiscal Q2 Revenue Beats 1%

Organon & Co. (NYSE:OGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer Kevin Ali - CEO & Director Matthew M. Walsh - Executive VP & CFO Conference Call Participants Alexandra Doering von Riesemann - Piper Sandler & Co., Research Division Ethan Harris Brown - JPMorgan Chase & Co, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Terence C.

The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Organon (OGN) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.12 per share a year ago.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon shares results for second quarter ended June 30, 2025.